This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
GE HealthCare (GEHC) Boosts Interventional Radiology Capabilities
by Zacks Equity Research
GE HealthCare's (GEHC) latest successful first installation and clinical cases using the OmnifyXR are likely to improve clinical and operational outcomes for both patients and clinicians.
3 Generative AI-Based MedTech Stocks to Keep an Eye On
by Moumi Mondal
With the growing influence of GenAI in the MedTech sector, innovators like ZBH, GEHC and MDT are poised to thrive.
GE HealthCare's (GEHC) New Tie-Up to Boost Patient Care in Mexico
by Zacks Equity Research
GE HealthCare's (GEHC) latest agreement is likely to standardize care protocols and improve the quality of CT, MR and ultrasound examinations.
GE HealthCare Technologies Inc. (GEHC) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
GE HealthCare (GEHC) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
GE HealthCare (GEHC), Medis Medical Partner to Aid CAD Therapy
by Zacks Equity Research
GE HealthCare (GEHC) and Medis Medical collaborate to boost precision care for coronary artery disease treatment.
GE HealthCare Technologies Inc. (GEHC) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
GE HealthCare (GEHC) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
GE HealthCare (GEHC) Unveils Head-Only MR Scanner SIGNA MAGNUS
by Zacks Equity Research
GE HealthCare's (GEHC) new SIGNA MAGNUS can delve deep into the brain's microstructure, microvasculature and function, providing researchers with a clearer picture of neurological diseases and disorders.
GE Healthcare's (GEHC) Revolution RT to Aid Cancer Treatment
by Zacks Equity Research
GE Healthcare (GEHC) unveils Revolution RT, along with other upgrades, from its portfolio during the ESTRO 2024 Congress.
Stock Market News for May 1, 2024
by Zacks Equity Research
U.S. stock markets tumbled Tuesday, closing sharply lower.
GE HealthCare (GEHC) Q1 Earnings In Line, Sales Volume Decline
by Zacks Equity Research
GE HealthCare's (GEHC) first-quarter results witness declining segmental revenues in imaging, ultrasound and patient care. The bottom line improves on better pricing.
GE HealthCare (GEHC) Reports Q1 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
While the top- and bottom-line numbers for GE HealthCare (GEHC) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
GE HealthCare Technologies (GEHC) Meets Q1 Earnings Estimates
by Zacks Equity Research
GE HealthCare (GEHC) delivered earnings and revenue surprises of 0% and 3.33%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
What's in Store for These 5 Medical Device Stocks in Q1 Earnings?
by Indrajit Bandyopadhyay
Here is a sneak peek into how the five medical device stocks, SYK, GEHC, ECL, NARI and MMSI, might fare in their quarterly results slated to be released tomorrow.
Rising Demand Likely to Aid GE HealthCare's (GEHC) Q1 Earnings
by Zacks Equity Research
GE HealthCare's (GEHC) first-quarter results are expected to report strong organic revenue growth, banking on balanced segmental performance driven by consistent NPIs and growing customer demand.
GE HealthCare (GEHC) Is Considered a Good Investment by Brokers: Is That True?
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in GE HealthCare (GEHC). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
GE HealthCare Technologies (GEHC) Laps the Stock Market: Here's Why
by Zacks Equity Research
GE HealthCare Technologies (GEHC) concluded the recent trading session at $86.21, signifying a +1.96% move from its prior day's close.
GE HealthCare's (GEHC) New Tie-Up to Boost Patient Outcomes
by Zacks Equity Research
GE HealthCare's (GEHC) latest partnership is likely to benefit global healthcare systems by enhancing Elekta's RT offerings with its MIM Software medical imaging management solutions.
Here's Why GE HealthCare Technologies (GEHC) Gained But Lagged the Market Today
by Zacks Equity Research
GE HealthCare Technologies (GEHC) reachead $84.55 at the closing of the latest trading day, reflecting a +0.07% change compared to its last close.
GE HealthCare's (GEHC) Voluson to Aid Women's Health Imaging
by Zacks Equity Research
GE HealthCare (GEHC) announces its latest AI-powered Voluson Signature 20 and 18 ultrasound systems, which are likely to provide effective and efficient care for conditions impacting women's health.
Investors Heavily Search GE HealthCare Technologies Inc. (GEHC): Here is What You Need to Know
by Zacks Equity Research
Zacks.com users have recently been watching GE HealthCare (GEHC) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
GE HealthCare (GEHC), RSNA Unite to Aid Breast Cancer Imaging
by Zacks Equity Research
GE HealthCare (GEHC) and RSNA collaborate to provide radiologists at Muhimbili National Hospital a test mammography technology and advanced imaging training to aid in the treatment of breast cancer.
GE HealthCare Technologies (GEHC) Stock Moves -0.17%: What You Should Know
by Zacks Equity Research
In the closing of the recent trading day, GE HealthCare Technologies (GEHC) stood at $86.13, denoting a -0.17% change from the preceding trading day.
GE HealthCare (GEHC) to Showcase Enhanced Breast Cancer Imaging
by Zacks Equity Research
GE HealthCare's (GEHC) latest breast cancer detection technology is likely to enhance the detection and diagnosis of breast cancer and improve patient outcomes.
Medtronic's (MDT) Sphere-360 PFA Study Outcome Favorable
by Zacks Equity Research
Medtronic's (MDT) Sphere-360 catheter is designed to simplify the atrial fibrillation process while increasing efficiency and giving long-lasting lesions.
Here's Why GE HealthCare Technologies (GEHC) Fell More Than Broader Market
by Zacks Equity Research
In the most recent trading session, GE HealthCare Technologies (GEHC) closed at $87.71, indicating a -0.86% shift from the previous trading day.